RTC
MLYS icon

Riverview Trust Company’s Mineralys Therapeutics MLYS Stock Holding History

Riverview Trust Company’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,353
Closed -$12.9K – 430
2023
Q3 		$12.9K Buy
+1,353
New +$17.6K 0.01% 615

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Riverview Trust Company's MLYS Position: Q4 2023 in Review

Riverview Trust Company sold out of Mineralys Therapeutics (MLYS) in Q4 2023, closing a stake of 1,353 shares — an estimated $12.9K sold.

Riverview Trust Company first reported a position in MLYS in Q3 2023 and held it in 1 quarter. The position peaked at $12.9K in Q3 2023. 87 funds tracked by Wall St. Rank hold MLYS as of Q4 2023.

  • Riverview Trust Company reported no remaining Mineralys Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Riverview Trust Company sold 1,353 Mineralys Therapeutics shares in Q4 2023, an estimated $12.9K.
  • Riverview Trust Company first reported a position in Mineralys Therapeutics in Q3 2023 and held it in 1 quarter.
  • Riverview Trust Company's Mineralys Therapeutics position peaked at $12.9K in Q3 2023.
  • 87 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2023.

Based on Riverview Trust Company's 13F filing for Q4 2023, filed 24 Jan 2024.